Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Ellie Handy is an associate in the London Life Sciences Industry Group. Ms. Handy advises clients working in the life sciences and technology sectors on both contentious and non-contentious regulatory matters.

Ms. Handy’s practice focuses on providing life sciences regulatory advice, primarily to pharmaceutical companies and medical device manufacturers. This includes advice on classification, data protection, clinical research, labelling and promotion, and reporting obligations. Ms. Handy also advises companies in the food, cosmetic and consumer products sectors regarding regulatory compliance and borderline issues.

  • Regulatory advice to pharmaceutical and biotechnology companies on various issues.
  • Regulatory advice to medical device manufacturers on various issues, in particular classification, regulatory infrastructure requirements and issues regarding placing on the market.
  • Advising on digital health issues to life sciences and technology companies.
  • Advising pharmaceutical and biotechnology companies, medical device, cosmetic, and consumer product manufacturers and food companies in relation to borderline issues.
  • Advising companies in the life sciences sector in relation to Brexit.
  • Regulatory due diligence for pharmaceutical, medical device and food companies.
  • Advising pharmaceutical companies on relevant promotion and marketing laws and codes of practice.
  • Advising a pharmaceutical company in potential judicial review proceedings.
  • Advising a pharmaceutical company involved in a NICE HST procedure.